A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Rexlemestrocel-L (Primary) ; Hyaluronic acid
- Indications Back pain; Intervertebral disc degeneration
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms HyaluronicAcid
- Sponsors Mesoblast
Most Recent Events
- 26 Feb 2025 According to a Mesoblast media release, the capital raise concluded last month will facilitate expansion of sites enrolling in this CONFIRMATORY phase 3 trial and acceleration of patient accrual.
- 21 Jul 2024 According to a Mesoblast media release, company announced patient enrollment commenced.
- 18 Jul 2024 Planned End Date changed from 1 Aug 2027 to 1 Oct 2027.